.* "N-Butyldeoxynoirimycin Is a Novel Inhibitor of Gly colipid Biosynthesis", Platt et al., The Journal of Biological Chemistry, vol. 269, No. 11, Mar. 18, 1994, pp. 8362-8365 . "N-Butyldeoxygalactonojirimycin Inhibits Glycolipid Bio synthesis but Does Not Affect N-Linked Oligosccharide Processing, Platt et al., The Journal of Biological Chem istry, vol. 269, No. 43, Oct. 28, 1994, pp. 27108-27114 . "Inhibitors of Glycosphingolipid Biosynthesis", Platt et al., Trends in Glycoscience and Glycotechnology, vol. 7, No. 38, Nov. 1995, pp. 495-511 .
"Prevention of Lysosomal Storage in Tay-Sachs Mice
Treated with N-Butyldeoxynoirimycin, Platt et al., Sci ence, vol. 276, Apr. 18, 197, . "Extensive Glycosphingolipid Depletion in the Liver and Lynphoid Organs of Mice Treated with N-Butyldeoxynojiri mycin, Platt et al., The Journal of Biological Chemistry, vol. 272, No. 31, Aug. 1, 1997, pp. 19365-19372 . "New Therapeutic Prospects for the Glycosphingolipid Lysosomal Storage Diseases, Platt et al., Biochemical Pharmacology, vol. 56, 1998, pp. 421-430 PCT/US98/125087 designating US (filed Dec. 10, 1998 and pending) and application Ser. No. 09/209,033 (filed Dec. 10, 1998 and pending); both of which claim priority benefit from provisional Applin. No. 60/069,245 (filed Dec. 11, 1997 and now abandoned).
This application also claims priority benefit from provi sional Applin. No. 60/130,711 (filed Apr. 22, 1999 and pending) .
FIELD OF THE INVENTION
The invention relates to the treatment of lipid storage disease with compounds that inhibit glucosyltransferase activity in the affected cells. It relates particularly to the use of 1,5-dideoxy-1,5-limino-D-glucitol and derivatives thereof.
BACKGROUND OF THE INVENTION
More than 40 million people worldwide are chronically infected with the hepatitis C virus (HCV), and this repre sents one of the most serious threats to the public health of developed nations (Hoofnagle et al., 1997, New Engl J Med 336:347-356) . Hepatitis C infection is the cause of more than 10,000 deaths annually in the United States (Hepatitis C Treatment, Washington Post, Nov. 11, 1997, at A2), a number that is expected to triple in the next twenty years in the absence of effective intervention. Chronic HCV also increases the risk of liver cancer. There are more than 40 million people worldwide who are chronically infected with HCV, representing one of the most Serious threats to the public health of developed nations (Hoofnagle et al., 1997) .
Persistent infection develops in as many as 85% of HCV patients and in at least 20% of these patients the chronic infection leads to cirrhosis within twenty years of onset of infection. With an estimated 3.9 million North Americans chronically infected, complications from Hepatitis C infec tion is now the leading reason for liver transplantation in the United States.
HCV is an RNA virus belonging to the Flaviviridae family. Individual isolates consist of closely related, yet heterologous populations of Viral genomes. This genetic diversity enables the virus to escape the host's immune System, leading to a high rate of chronic infection. A large number of individuals who are infected with HCV are also infected with HBV. The therapy for combined HBV/HCV infection is particularly challenging because the HBV and HCV viruses differ from one another in therapeu tically significant ways. HBV is a hepadnavirus, while HCV is a pestivirus. HBV is a DNA-containing virus, the genome of which is replicated in the nucleus of the infected cell using a combination of a DNA-dependent RNA polymerase and an RNA-dependent DNA polymerase (i.e., a reverse transcriptase). HCV is an RNA-containing virus, the genome of which is replicated in the cytoplasm of the infected cell using one or more types of RNA-dependent RNA polymerases. Despite the frequent concurrence of HBV infection and HCV infection, a number of compounds known to be effective for treating HBV infection are not effective against HCV. For example, lamivudine (the nucleo side analog 3TC) is useful for treating HBV infection, but is not useful for treating HCV infection. The difference in the susceptibility of HBV and HCV to antiviral agents no doubt relates to their genetically based replicative differences. There remains a particularly critical need for a therapeutic intervention that effectively treats both HBV and HCV infection.
Animal viruses that acquire their envelope from a mem brane associated with the intracellular membrane of an infected animal cell cause significant losses to the livestock industry (Sullivan et al., 1995, Virus Res 38:231-239) . Such animal viruses include pestiviruses and flaviviruses Such as bovine viral diarrhea virus (BVDV), classical Swine fever Virus, border disease virus, and hog cholera virus.
The flavivirus group to which HCV belongs is known to include the causative agents of numerous human diseases transmitted by arthropod vectors. Human diseases caused by flaviviruses include various hemorrhagic fevers, hepatitis, and encephalitis. Viruses known to cause these diseases in humans have been identified and include, for example, yellow fever virus, dengue Viruses 1-4, Japanese encepha litis virus, Murray Valley encephalitis virus, Rocio virus, West Nile fever virus, St. Louis encephalitis virus, tick borne encephalitis virus, Louping ill virus, Powassan virus, Omsk hemorrhagic fever virus, and Kyasanur forest disease Virus. A critical need therefore also exists for treating animals, as well as humans, infected with a flavivirus or a pestivirus.
SUMMARY OF THE INVENTION
The invention provides a method of inhibiting morpho genesis of a virus which acquires its envelope from a membrane associated with the intracellular membrane of an infected cell, the method comprising administering to the cell a glucosidase inhibitor in an amount effective to inhibit the activity of a glucosidase enzyme associated with the endoplasmic reticulum of the cell. In one aspect, the virus is Selected from the group consisting of a flavivirus and a pestivirus, Such as a Hepatitis C virus, a bovine viral diarrhea virus, a classical Swine fever virus, a border disease Virus, or a hog cholera virus. In another aspect, the mem brane is Selected from the group consisting of a membrane that Surrounds the lumen of the endoplasmic reticulum and a membrane that Surrounds a lumen of the Golgi apparatus.
In a preferred embodiment of the invention, the glucosi dase inhibitor is 1,5-dideoxy-1,5-limino-D-glucitol or a 3 derivative thereof Selected from the group consisting of an N-alkyl, N-acyl, N-aroyl, N-aralkyl, and O-acyl derivatives. The invention includes a method of inhibiting morpho genesis of a virus that acquires its envelope from an internal cell membrane associated with the endoplasmic reticulum (ER). The method comprises administering a glucosidase inhibitor to the cell in an amount effective to inhibit the activity of a glucosidase enzyme associated with the endo plasmic reticulum of the cell, thereby inhibiting morpho genesis of the virus. Mammalian cells infected with the Subject viruses including, but not limited to, human liver cells and bovine monocytes are particularly contemplated as therapeutic targets.
The invention also includes a method of treating an animal infected with a virus that is characterized by acquir ing its envelope from a membrane associated with the ER of a virus-infected cell. The method comprises administering a glucosidase inhibitor to the animal in an amount effective to inhibit the activity of a glucosidase enzyme with the endo plasmic reticulum of a virus-infected cell of the animal, thereby reducing, ablating, or diminishing the virus infection in the animal. The animal is preferably a mammal Such as a pig or a cow and, particularly, a human being.
The methods of the invention are useful for inhibiting morphogenesis of a virus, or for treating an animal infected with any virus that acquires its envelope from a membrane associated with the ER. Because both flaviviruses and pes tiviruses acquire their envelopes from membranes associ According to yet another aspect of the invention, there is provided a method for targeting a glucosidase inhibitor or glucosyltransferase inhibitor to the liver cell of an animal by targeting Said liver. cells with an N-alkyl derivative of a 1,5-dideoxy-1,5-limino-D-glucitol. In a preferred embodi ment the derivative is an N-nonyl-1,5-dideoxy-1,5-limino D-glucitol.
According to another aspect of the invention there is provided a method for treating lipid storage disease, where a glucosyl-or galactosyl-linked lipid accumulates in the cells of the affected individual. In one embodiment of this aspect of the invention the method comprises treating a lySOSomal Storage disease in an animal by administering an effective glucosyltransferase-inhibiting amount of an N-nonyl-1,5-dideoxy-1,5-limino-D-glucitol derivative to the affected cells of said animal, whereby the production of glycolipids in Said cells is limited. In a preferred embodi ment of this aspect of the invention, the animal is affected with Tay-Sachs, Gaucher, Krabbe, or Fabry disease.
According to yet another aspect of the invention there is provided a prophylactic method for protecting a mammal infected by a virus that acquires a viral component from an internal membrane of an animal cells from developing a cancer that is among the Sequelae of infection by Said virus, comprising administering to the virus infected cell of the 
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
Infections by viruses that require host cell glycosidase enzymes to Synthesize and properly fold viral envelope glycoproteins can be treated by administering an inhibitor of those enzymes to the host cell. A target virus is any virus that acquires a component of its envelope in cooperation with internal cell membrane associated with the endoplasmic reticulum (ER). Preferred viruses are members of the fla Vivirus or pestivirus class.
By a "membrane associated with the ER" of a cell is meant a membrane which Surrounds the lumen of the ER of the cell, a membrane which Surrounds a lumen of the Golgi apparatus (GA), a membrane which Surrounds the lumen of a vesicle passing from the ER to the GA, a membrane which Surrounds the lumen of a vesicle passing from the GA to the ER, a membrane which Surrounds the lumen of a vesicle passing from the GA or the ER to the plasma membrane of the cell, a membrane which Surrounds the lumen of a vesicle passing from the GA or the ER to the nuclear membrane of the cell, or a membrane which Surrounds the lumen of a vesicle passing from the GA or the ER to a mitochondrial membrane of the cell. It is contemplated that the methods of the invention are preferably applied to inhibiting the pro duction of a virus that acquires any morphogenetic compo nent by derivation from any of the internal membranes of the host cell.
By a "glucosidase enzyme associated with the ER" of a cell is meant a glucosidase enzyme which is embedded within, bound to the luminal side of, or contained within a membrane associated with, the ER of the cell. By way of example, mammalian C-glucosidase I and mammalian C-glucosidase II are glucosidase enzymes associated with the ER of a mammalian cell.
A virus-infected animal cell which is treated according to the methods of the invention may be any cell that comprises a glucosidase enzyme associated with an internal membrane of the cell, preferably an enzyme associated with the endo plasmic reticulum (ER). Treatment of mammalian cells, including but not limited to human liver cells and bovine monocytes, are particularly preferred.
Agents that exhibit an inhibitory effect on glucosidases are believed to do So because they are Structural analogs of glucose. One of these agentS is the imino Sugar designated 1,5-dideoxy-1,5-limino-D-glucitol (or deoxynojirimycin, hereinafter DNJ). Numerous DNJ derivatives have been It is believed that DNJ exhibits its inhibitory effects on glucosidase because it is a glucose analog. However, Bryant discloses no mechanism by which DNJ derivatives exhibited the observed anti-RSV activity. RSV, a paramyxovirus, acquires its envelope from the plasma membrane of an RSV-infected cell. Thus, morphogenesis of HIV virions which are believed to bud through the plasma membrane, appears to be unaffected by the presence of NBDNJ. However, the infectivity of the virus particles released from HIV-infected cells exposed to NBDNJ is greatly reduced relative to HIV particles released from cells which were not exposed to NBDNJ (Dedera et al., 1990; Fischer et al., 1995; Taylor et al., 1994) . These studies suggest that the anti-HIV properties of NBDNJ are the result of improper viral fusion of target cells, rather than direct inhibition of HIV budding from cells.
More recently we demonstrated the anti-viral effect of glucosidase inhibitors in a woodchuck animal model of HBV infection. In woodchucks chronically infected with woodchuck hepatitis virus (WHV), treatment with ER C-glucosidase inhibitors results in the disruption of the proper folding and transport of Viral envelope glycoproteins and prevents the Secretion of infectious enveloped virus (Block et al., 1998, Nature Med 4:610-614 ).
Most Significantly and apparently different from the Situ ation with HIV and RSV, inhibition of only modest amounts of glucosidase resulted in massive inhibition of HBV and BVDV secretion. This suggests that, unlike with HIV and RSV, etc., for viruses that bud from internal membranes, disruption of only a minority of envelope viral proteins is sufficient to inhibit secretion of the virus. This may be due to the fact that our evidence suggests that disrupted HBV and BVDV viral proteins act as "dominant negative' poi Sons of Virus Secretion and may themselves be considered the antiviral drug, as much as the drug itself. 7 ER C-glucosidases are responsible for the Stepwise removal of terminal glucose residues from N-glycan chains attached to nascent glycoproteins. This enables the glyco proteins to interact with the ER chaperones calnexin and calreticulin, which bind eXclusively to mono-glucosylated glycoproteins. Interaction with calnexin is crucial for the correct folding of Some but not all glycoproteins, and inhibitors of the glucosidases can be used to Specifically target proteins that depend on it. N-linked glycans play many roles in the fate and functions of glycoproteins. One function is to assist in the folding of proteins by mediating interactions of the lectin-like chaperone proteins calnexin and calreticulin with nascent glycoproteins. It is these inter actions that can be prevented by inhibiting the activity of the C-glucosidases with agents such as N-butyl-DNJ and N-nonyl-DNJ, causing some proteins to be misfolded and retained within the endoplasmic reticulum (ER). We have The exquisite sensitivity of HBV to alterations in the envelope proteins induced by C-glucosidase inhibition and the fact that it is not necessary to inhibit the enzyme to any great extent in order to achieve the observed anti-Viral effect, led us to Speculate that the Sensitivity of the virus may be due to the fact that it has to oligomerize and assemble the envelope in the ER where folding takes place. Unlike the situation with HIV and RSV, a few misfolded envelope proteins may be Sufficient to disrupt the proper envelopment proceSS and amplify the adverse effect the inhibitor has on Virus assembly as compared to the effect it has on host cell proteins, which do not seem to be impaired at anti-viral inhibitor concentrations. Our mechanism Studies led us to propose that other viruses which acquire their envelopes from intracellular membranes such as the ER would be equally Sensitive to ER C-glucosidase inhibition, provided one or more of their glycoproteins depended on calnexin mediated folding.
Although HBV and HCV have completely different life cycles, they have three things in common: They target the liver, they bud from the ER and other internal membranes and their envelope glycoprotein(s) fold via a calnexin dependent pathway. This prompted us to investigate whether the same inhibitors shown to have an anti-viral effect on HBV could inhibit HCV by the same proposed mechanism.
The two HCV envelope glycoproteins E1 and E2, which contain five or six and eleven N-linked glycosylation sites, respectively, both interact with calnexin during productive folding (Choukhi et al., 1998, J Virol 72:3851-3858) . Due to the lack of an efficient cell culture replication System the understanding of HCV particle assembly is very limited. However, the absence of complex glycans, the localization of expressed HCV glycoproteins in the ER, and the absence of these proteins on the cell Surface Suggest that initial virion morphogenesis occurs by budding into intracellular vesicles from the ER. Additionally, mature E1-E2 heterodimers do not leave the ER, and ER retention signals have been identified in the C-terminal regions of both E1 and E2.
This led us to investigate the effect of glucosidase inhibi tors on another ER-budding virus, bovine viral diarrhea virus (BVDV), the tissue culture surrogate of human hepa titis C virus (HCV). In the absence of a suitable cell culture system able to support replication of human HCV, bovine viral diarrhea virus (BVDV) serves as the FDA approved model organism for HCV (FIG. 1) , as both share a signifi (E1) and gp53 (E2), and 8 potential N-glycosylation sites in the region encoding for gp48 (EO), a hydrophilic Secreted protein of unknown function. The Structures of the oligosac charides attached to any of these glycoproteins remain to be determined. BVDV proved to be even more sensitive to ER C-glucosidase inhibitors. This and the facts that the inhibi tors used are preferentially taken up by liver-type cells in vitro and exhibit a prolonged retention in the liver in vivo give rise to the exciting possibility that glucosidase inhibi tors could be used as broad based antiviral hepatitis agents. Herein we describe the sensitivity of BVDV to glucosi dase inhibition and discuss the possible reasons for ER-budding viruses being Selectively dependent upon gly can processing. We have discovered that cytotoxicity result ing from exposure of mammalian cells in tissue culture to The compounds are used as the imino-protected Species or the di-and tetra-acetates, propionates, butyrates, isobu tyrates of the imino protected Species. Methods of synthesizing DNJ derivatives are known and are described, for example, in U.S. Pat. Nos. 5, 622, 972, 4, 246, 345, 4, 266, 025, 4, 405, 714, and 4, 806, 650 The substituents on the basic 1,5-dideoxy-1,5-limino-Dglucitol can influence the potency of the compound as an antiviral agent and additionally can preferentially target the molecule to one organ rather than another. For example, the N-butyl-substituted DNJ is less potent than the N-nonyl subsituted-DNJ in inhibiting the intracellular production of The DNJ derivatives described herein may be used in the free amine form or in a pharmaceutically acceptable Salt form. Pharmaceutical Salts and methods for preparing Salt forms are provided in Berge et al. (1977, J Pharm Sci 66:1-18) . A salt form is illustrated, for example, by the HCI salt of a DNJ derivative. DNJ derivatives may also be used in the form of prodrugs. Such as the 6-phosphorylated derivatives described in U.S. Pat. Nos. 5,043,273 and 5,103, 008. Use of compositions which further comprise a phar maceutically acceptable carrier and compositions which further comprise components useful for delivering the com position to an animal are explicitly contemplated. Numerous pharmaceutically acceptable carriers useful for delivering the compositions to a human and components useful for delivering the composition to other animals. Such as cattle are known in the art. Addition of Such carriers and compo nents to the composition of the invention is well within the level of ordinary skill in the art.
The methods of the invention may further comprise use of a DNJ derivative and a Supplemental antiviral compound. The Supplemental antiviral compound may be any antiviral agent, which is presently recognized, or any antiviral agent which becomes recognized. By way of example, the Supple mental antiviral compound may be interferon-alpha, 
Treatment of Lipid Storage Diseases
Member of a group of lipidoses or lipid storage diseases in which glucosyl or galactosyl residues incorporated into complex lipids accumulate in the tissues can be treated using the glucosyltransferase inhibiting compounds of the invention, particularly N-nonyl-1,5-dideoxy-1,5-limino-Dglucitol according to the methods of the invention. Among these lipidoses are:
Gaucher Disease A familial autosomal recessive disorder of lipid metabo lism resulting in an accumulation of abnormal glucocerebro Sides in reticuloendothelial cells, and manifested clinically by hepatosplenomegaly, skin pigmentation, Skeletal lesions and pingueculae.
The underlying defect in this disease is the lack of glucocerebrosidase activity, which normally hydrolyzes glu cocerebroside to glucose and ceramide. The typical patho logical finding is widespread reticulum cell hyperplasia. The cells are filled with glucocerebroside and a fibrillar cytoplasm, vary in shape and have one or Several Small eccentrically placed nuclei. These reticulum cells are found in the liver, Spleen, lymph nodes and bone marrow.
Krabbe's Disease (Galactosylceramide Lipidosis) A familial lipid Storage disorder Secondary to a deficiency of galactocerebroside 3-galactosidase. A fatal infantile dis order characterized by progressive retardation, paralysis, blindness, deaffieSS and pseudobulbar palsy.
Fabry's Disease (Galactosylgalactosylglucosyl Ceramide Lipidosis)
A familial disorder of lipid metabolism in which gly colipid accumulates in the many tissues. The metabolic disorder is caused by a deficiency of the lySOSomal enzyme O-galactosidase as required for the metabolism of triheXo Sylceramide. Affected individuals have skin lesions and corneal opacities.
Tay-Sachs Disease: (GM2 Gangliosidosis)
A familial recessive disorder caused by deficiency of the enzyme hexosaminidase A, resulting in the accumulation of gangliosides (complex Sphingolipids, comprising oligosac charides made up of glucose and galactose) in the brain.
The amount of antiviral agent administered to an animal or to an animal cell according to the methods of the invention is an amount effective to inhibit the activity of a glucosidase enzyme associated with the ER or other internal membranes in the cell. The amount of glucosyltransferase inhibitor administered to an animal or an animal cell accord ing to the methods of the invention is an amount Sufficient to inhibit the activity of a glucosylotransferase enzyme associated with the ER or other internal membranes in the cell. The term "inhibit as used herein refers to the detect able reduction and/or elimination of a biological activity exhibited in the absence of a DNJ derivative compound according to the invention. The term "effective amount" refers to that amount of composition necessary to achieve the indicated effect. The term "treatment" as used herein refers to reducing or alleviating Symptoms in a Subject, preventing Symptoms from worsening or progressing, inhi bition or elimination of the causative agent, or prevention of the infection or disorder in a subject who is free therefrom.
Thus, for example, treatment of a patient affected with lipidosis may be reduction of lipid accumulation in the affected cells, the prevention of progressive disease in a patient who has been treated. Treatment of viral infection includes destruction of the infecting agent, inhibition of or interference with its growth or maturation, neutralization of its pathological effects, and the like. The amount of the composition which is administered to the cell or animal is preferably an amount that does not induce any toxic effects which outweigh the advantages which accompany its admin istration.
Actual dosage levels of active ingredients in the pharma ceutical compositions of this invention may be varied So as to administer an amount of the active compound(s) that is effective to achieve the desired therapeutic response for a particular patient.
The selected dose level will depend on the activity of the Selected compound, the route of administration, the Severity of the condition being treated, and the condition and prior medical history of the patient being treated. However, it is within the skill of the art to start doses of the compound(s) at levels lower than required to achieve the desired thera peutic effect and to gradually increase the dosage until the desired effect is achieved. If desired, the effective daily dose may be divided into multiple doses for purposes of administration, for example, two to four doses per day. It will be understood, however, that the specific dose level for any particular patient will depend on a variety of factors, including the body weight, general health, diet, time and route of administration and combination with other drugs and the Severity of the disease being treated. It is expected 12 that the adult human daily dosage will normally range from between about one microgram to about one gram, preferably from between about 10 mg and 100 mg, of the glucosidase inhibitor per kilogram body weight. Of course, the amount of the composition which should be administered to a cell or animal is dependent upon numerous factors well understood by one of skill in the art, Such as the molecular weight of the glucosidase inhibitor, the route of administration, and the like.
Pharmaceutical compositions that are useful in the meth ods of the invention may be administered Systemically in oral Solid formulations, ophthalmic, Suppository, aerosol, topical, or other Similar formulations. In addition to the glucosidase-or glucosyltransferase-inhibitor, Such pharma ceutical compositions may contain pharmaceutically acceptable carriers and other ingredients known to enhance and facilitate drug administration. Other possible formulations, Such as nanoparticles, liposomes, resealed erythrocytes, and immunologically based Systems may also be used to administer the glucosidase-or glucosyltransferase-inhibitor according to the method of the invention. Such pharmaceutical compositions may be administered by any known route. The term "parenteral" used he rein includes Subcutaneous, intravenous, intraarterial, intrathecal, and injection and infusion techniques, without limitation. By way of example, the pharmaceutical compositions may be administered orally, topically, parenterally, Systemically, or by a pulmonary rOute.
These compositions may be administered according to the methods of the invention in a single dose or in multiple doses which are administered at different times. Because the inhibitory effect of the composition upon a virus endures longer than the inhibitory effect of the composition upon normal host cell protein glucosylation, the dosing regimen may be adjusted Such that Virus propagation is retarded while host cell protein glucosylation is minimally effected. By way of example, an animal may be administered a dose of the composition of the invention once per week, whereby Virus propagation is retarded for the entire week, while host cell protein glucosylation is inhibited only for a short period once per week.
One advantage of administering these compositions is that they inhibit an enzyme of the host, rather than a viral function. It is well known that Viruses are capable of mutating, whereby a viral function which is Susceptible to inhibition by an antiviral agent mutates Such that it becomes resistant to inhibition by the agent in progeny Viruses. By way of example, the ability of the HIV virus to mutate such that it is rendered impervious to a particular anti-viral agent Such as AZT is well documented. The methods of the invention have the advantage that the composition used in the methods targets a host cell function employed by a virus as a part of its life cycle. This host function, namely glucosylation catalyzed by a host glucosidase associated with the host cell's ER or glucosyl transfer catalyzed by a host glucosyltransferase associated with the host cell's ER, is not Subject to alteration brought about by a mutation in the genome of the virus. Thus, Strains of the virus which are resistant to inhibition by the composition of the invention are unlikely to develop.
Experimental Procedures
It was observed in the present invention that NBDNJ inhibited the ability of BVDV to form plaques on MDBK cell monolayers in tissue culture. By way of example, in two cultures which were exposed to BVDV but not to NBDNJ, there were 16 and 25 Viral plaques in the Wells containing 13 the infected cells. Cells cultures which were exposed to BVDV and which were exposed to NBDNJ immediately after infection yielded no visible plaques, and the cell monolayerS appeared healthy and viable, as assessed by neutral red Staining.
Bovine viral diarrhea virus (BVDV) was used in these experiments as a Surrogate for HCV. The use of a Surrogate for HCV in tissue culture is necessary because HCV cannot be reliably propagated in tissue culture, nor in animals other than humans and chimpanzees. Like HCV, BVDV is a pestivirus that is believed to bud from the ER (Harasawa et al., 1995, Microb Immunol 39:979-985) . BVDV is consid Darby Bovine Kidney (MDBK) cells. Using plaque reduc tion and yield assays (Example 2), the nonyl compound (ICso-2.5uM) was shown to be forty-six times more potent than the butyl compound (IC=115uM).
To the extent that N-nonyl-DNJ is a much more potent inhibitor of glucosyltransferase activity in cell-based assays than is N-butyl-DNJ and inhibition of glucosyltransferase activity may be useful in treating many lysosomal glycolipid storage diseases (Platt et al., 1997, Science 276:428-431) , it is appreciated that nonyl DNJ and other alkyl chain deriva tives of DNJ may be valuable in treating lysosomal gly colipid storage diseases Such as Tay-Sachs, Gaucher disease, Fabry disease and the like. As both NB-DNJ and NN-DNJ compounds inhibit not only the ER CL-glucosidases, but also a ceramide Specific glucosyltransferase that is involved in glycosphingolipid biosynthesis, it was necessary to establish via which pathway these drugs exert their antiviral effect. The two pathways were pharmacologically dissected using N-butyl-deoxygalactonojirimycin (NB-DGJ), an inhibitor that targets only the glucosyltransferase. In the plaque reduction assay NB-DGJ had no effect on BVDV plaque formation (FIG. 3) . The concentrations of NB-DGJ used were Sufficient to completely inhibit the glucosyltransferase, as shown by the dose-dependent decrease of Glc-ceramide and gangliosides in "C-palmitate-labeled NB-DGJ-treated MDBK cells (data not shown). This shows that the antiviral effect observed with NB-DNJ and NN-DNJ is due to the inhibition of the ER CL-glucosidases involved in N-glycan processing.
Golgi endo-C-D-mannosidase, an enzyme which can pro vide an alternate pathway for achieving deglucosylation, thereby allowing even glucosidase-inhibited glycans to be further processed to complex-type oligosaccharides, has been shown to be present at Substantial levels in MDBK cells. However, not all proteins can necessarily make use of this pathway. For example, the VSV-G protein remains endo-H-Susceptible during a castanospermine imposed glu cosidase blockade in MDBK cells. Therefore, treating MDBK cells with NB-DNJ and NN-DNJ may also prevent the BVDV envelope glycoproteins from acquiring complex type N-glycans, which may be crucial for viral Secretion. To (FIG. 4) . DMJ, which prevents the formation of complex type N-glycans without interfering with earlier Steps in N-glycan biosynthesis had no effect on BVDV plaque for mation. This means that the antiviral effect of NB-DNJ and NN-DNJ is mediated by a step prior to complex N-glycan formation.
As NB-DNJ targets a host cell enzyme, other N-glycosylated host proteins, including the viral receptor, may be functionally impaired. If that was the case the virus might be prevented from entering the host cell. To test this possibility, MDBK cells were grown in the absence or presence of 1 mg/ml of NB-DNJ for up to six days prior to infection with the virus. Pretreatment with the drug did not prevent viral entry (data not shown), showing that the viral receptor is functional in glucosidase-inhibited cells.
In infectious virus as long as NB-DNJ is maintained in the culture medium and glucosidase is inhibited. We wanted to determine how long it would take the virus to recover from the effects of the glucosidase block and resume Secretion after removal of inhibitor. Infected cells were treated with either 1 mg/ml NB-DNJ or 30 ug/ml NN-DNJ for two days (i.e., until plaques in untreated controls were fully developed), before the drug-containing medium was removed and replaced by drug-free (minus drug) or drug containing (plus drug) medium. The medium was then removed at certain timepoints and assayed for infectious material using plaque reduction and yield assayS. No infec tious material was detected up to twenty-four hours after removal of the drug and the virus started to rebound only between the twenty-four and forty-eight hours time points (FIG. 6) .
The imino Sugars are reversible inhibitors of glucosidase and glucosyltransferase activity returns to near normal within two hours after drug removal. Yet the antiviral effect of N-nonyl-DNJ and N-butyl DNJ lasts long after two hours of removal (FIG. 6) and noted for HBV (Lu et al., 1997) . It is therefore proposed that the antiviral effect of the imino Sugar inhibitors is actually mediated by long-lived defective Viral glycoproteins persisting in the cell long after drug removal. These long-lived defective glycoproteins act in a dominant negative fashion and may thus be considered the 15 true antiviral agents themselves. The realization that the defective glycoproteins act as antiviral agents is inventive and will be useful in the treatment and development of new treatments for infections due to these viruses. The invention is now described with reference to the following Examples. The examples are provided for the purpose of illustration only and the invention should in no way be construed as being limited thereby but rather should be construed to encompass any and all variations which become evident as a result of the teaching provided herein. Experimental In the absence of a suitable cell culture system able to support replication of human HCV, bovine viral diarrhea virus (BVDV) serves as the FDA approved model organism for HCV (FIG. 1) , as both share a significant degree of local protein region homology (Miller et al., 1990) , common replication Strategies, and probably the same Sub-cellular location for Viral envelopment. Compounds found to have an antiviral effect against BVDV are highly recommended as potential candidates for treatment of HCV. Plaque Reduc tion and Yield Assays. MDBK cells were grown in six-well plates in the presence or absence of inhibitor (see Figure  legends) , infected with cp BVDV (moi=0.005; 500 pfu per well) for one hour at 37° C. The inoculum was then replaced with growth medium alone or with growth media and the antiviral agent and incubated for two or three days in the presence or absence of inhibitor (plaque reduction assay).
After counting the plaques by eye under the microscope, the Supernatant containing Secreted infectious virus was removed from the wells and used to infect a fresh monolayer of MDBK cells in six-well plates. After three days the resulting plaques were counted under the microscope (yield assay). 
EXAMPLE 2
Secretion of Infectious BVDV in the Presence of N-butyl-DNJ and N-nonyl-DNJ MDBK cells were grown to semi-confluence in individual wells of 24-well trays. The cells were then infected by BVDV by incubating the cells for one hour at 37° C. in the presence of approximately 500 PFU of the NADL strain of BVDV Suspended in growth medium. The inoculum was then replaced with growth medium alone or growth medium containing the concentration of NBDNJ or NNDNJ indi cated in Table 2 and Table 3 , respectively. After three days the Supernatants were removed and used to infect fresh MDBK monolayers in six-well plates. After three days, the cell monolayers were observed microscopically before and after staining with 0.2% (w/v) crystal violet in ethanol for plaque counting, and 0.2% neutral red for viability and the presence and number of Virus-induced plaques was deter mined. The results were expressed as percentages of the number of plaques resulting from infection with the inhibitor-free plaque assay supernatant (=100%). The results of these experiments are presented in Tables 2 and 3 It is not clear whether the number or merely the size of Virus-induced plaques was reduced by exposing the cells to NB-DNJ or NN-DNJ. There was no visible cytopathic effect in cells infected with BVDV and exposed to either 200 micrograms per milliliter NB-DNJ or 10 micrograms per milliliter NN-DNJ. Exposure of cells to 1000 micrograms per milliliter NB-DNJ did not result in measurable toxicity. Exposure of cells to 50 micrograms per milliliter NN-DNJ resulted in a monolayer in which cells had a "stressed" appearance, although no toxic effect could be quantified by Vital Staining.
The experimental results indicate that NN-DNJ and NB-DNJ are highly effective anti-BVDV drugs. Because BVDV infection is the most relevant model of HCV infec tion available in tissue culture and because BVDV and HCV are biochemically, Virologically, and genetically very similar, these data clearly indicate that NN-DNJ and NB-DNJ are also highly effective anti-HCV drugs. showed that the ceramide-specific glucosyltransferase was inhibited at concentrations which had no antiviral effect.
EXAMPLE 4
Control Assay for the Inhibition of Complex Sugar Formation by DMJ. MDBK cells were grown for three days in the absence/ presence of 300 tug/ml DMJ. The cells were stained with Erythrina cristagalli (ECA) lectin (28 ug/ml and 280 ug/ml), which recognizes the GalfGalNAc epitope, and analyzed by 
